Neurotez, Inc., Announced That It Has Contracted with Paragon Bioservices, Inc. for the Manufacturing of a Leptin Product for the Treatment of Alzheimer’s Disease and Other Cognitive Disorders
BRIDGEWATER, N.J.— December 20, 2010— Neurotez, Inc., announced that it has developed two (2) Leptin products for the treatment of Alzheimer’s disease and other cognitive disorders and has contracted with Paragon Bioservices, Inc. for process optimization and GMP manufacturing of one of these products.
Neurotez, Inc. will be presenting at the OneMedForum conference at the Sir Francis Drake Hotel in San Francisco on Jan 11, 2011.
About Paragon Bioservices, Inc.
Paragon Bioservices is a contract research and manufacturing organization (CMO) that provides a comprehensive portfolio of services--including process development, GMP manufacturing and cell banking. Paragon's focus is to bridge the translational divide, to enable protein and cell-based therapeutics into clinical trials. Our experienced process engineers, regulatory compliance associates and project managers work with our clients, from start to finish. For more information about Paragon Bioservices, please visit www.paragonbioservices.com .
About Neurotez, Inc.
Neurotez Inc., founded in 2005, is a privately held Delaware corporation operating from New Jersey, formed to develop a Leptin product as a hormone replacement therapy for Alzheimer's disease, and as a preventative remedy to those at risk.
Neurotez currently uses biochemical, molecular & cell biology and in vivo models to screen, identify and characterize suitable candidate biopharmaceuticals targeting major Central Nervous System (CNS) disorders with unmet medical need.
Neurotez aims to build a CNS biotechnology company with a fully-integrated platform that spans activities from discovery efforts to proof of concept clinical trials.
To find out more, please visit www.neurotez.com .